OUR SCIENCE
Pipeline

At Sylentis we are committed to health care and that is why we research and develop compounds that improve patients’ lives. We are currently developing a pipeline of products for the treatment of the following ophthalmological pathologies:

Investigation preclinical phase 1 phase 2 phase 3 registration
Ophthalmology
Dry eye disease Tivanisiran
(SYL1001)

Macular degeneration SYL1801

Ocular allergies SYL116011

Retinitis pigmentosa SYL A
SYL B

Technology development
Controlled release Formulations

Modifications